

- 0
- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; [or] and
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding[;
- as an immunomodulator for a vaccine against infectious diseases].

In claim 2 at line 1, change "The use" to --A method--.

In claim 3 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 4 at line 1, change "The use" to --A method--.

In claim 5 at line 1, change "The use" to --A method--.

In claim 6 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 7 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 8 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 9 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 10 at line 1, change "The use" to --A method--.

In claim 11 at line 1, change "The use" to --A method--.

In claim 12 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 13 at line 1, change "The use" to --A method--.

In claim 14 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 15 at line 1, change "The use" to --A method--.

In claim 16 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 17 at line 1, change "The use" to --A method--.

In claim 18 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 19 at line 1, change "The use" to --A method--.

~~In claim 20 at line 1~~, change "The use" to --A method-- and delete "or 2".

In claim 21 at line 1, change "The use" to --A method--.

In claim 22 at line 1, change "The use" to --A method-- and delete "or 2".

In claim 23 at line 1, change "The use" to --A method--.

31 (Amended). [The use of]: A method for upgrading the production of antibodies at mucosal surfaces in a mammalian subject comprising administering to the subject an effective amount of an immunomodulator selected from the group consisting of:

- 5 (i) EtxB, CtxB or VtxB free from whole toxin;
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; [or] and
(iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding
- 10 [to upregulate the production of antibodies at mucosal surfaces].

32. [The use of] A method for prolonging antigen presentation of, and giving sustained immunological memory to, a vaccine in a mammalian subject comprising administering to the subject an immunomodulator selected from the group consisting of:

- 5 (i) EtxB, CtxB or VtxB free from whole toxin;
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; [or] and
(iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding[;
- 10 as an immunomodulator in a vaccine, to prolong antigen presentation and give sustained immunological memory in a mammalian subject].

In claim 33 at line 5 (i.e., page 44, line 30), add --the group consisting of-- after "from" and at line 9 (i.e., page 44, line 34), change "or" to --and--.

34 (Amended). [The use of] A method for targeting delivery of a vaccine antigen or antigenic determinant to the cytosol or nucleus of an antigen-presenting cell upon administration of the vaccine to a mammalian subject comprising administering to the subject a conjugate comprising:

- 5 (i) EtxB, CtxB or VtxB free from whole toxin;
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
(iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or Gb3 binding;
- 10 [in a conjugate with] and said antigen or antigenic determinant [to target the delivery or said antigen or antigenic determinant to the cytosol or nucleus of an antigen presenting cell].